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Introduction
In recent years, PARP inhibitors such as
Olaparib, have been established as a proficient
strategy to treat homologous recombination
(HR) deficient cancers such as ovarian and
breast cancer. But it is less efficient to treat
homologous recombination efficient and RAS
mutant tumors. We attempted to identify
candidates whose loss of function can make
homologous recombination efficient and make
RAS mutant tumors more sensitive to PARP
inhibitor treatment. We performed genomewide CRISPR knockout (KO) screens in
ovarian and colorectal cancer cell lines in
presence of PARPi (Olaparib). We identified
several key components of the DNA damage
repair pathway such as BRCA1, BRCA2,
RAD50, FANCD2 and FEN1. In addition to
these known players in the DNA damage
repair pathway, we found UBA1 (a major
ubiquitination activation enzyme) as a top
depleted gene. We validated the CRISPR
screen finding by using siRNAs targeting
UBA1 and found that depletion of UBA1,
sensitizes ovarian, breast and colorectal cancer
cell lines to PARPi treatment.

Results & Figures

Conclusions

Fig. 1. Results of the sequencing analysis from the genome-wide CRISPR knockout displayed depletion of several homologous
recombination genes in both cancer cell lines. We identified that UBA1 was significantly depleted, suggesting that it could make
cells more sensitive to Olaparib treatment.

Our CRISPR KO screens identified several
key components of the DNA damage repair
pathway such as BRCA1, BRCA2, RAD50,
FANCD2 and FEN1. In addition to these
known players in the DNA damage repair
pathway, we found UBA1 (a major
ubiquitination activation enzyme) as top
depleted gene in both CRISPR KO screens.
Further we validated the CRISPR KO
findings and found that depletion of UBA1,
sensitizes ovarian, breast, and colorectal
cancer cell lines to PARPi treatment. To
conclude, our study suggests that the
combination of PARPi with UBA1 inhibitor
could be a potential therapeutic target for HR
efficient and RAS mutant tumours.

Future Research
We planned to mechanistically dissect the
synergy between PARP and UBA1 inhibitor.
We planned to further investigate the efficacy
of Olaparib treatment with UBA1 inhibitor
(TAK243) in vivo by using ovarian, breast,
and colorectal xenograft model.
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Fig. 2. Western blot analysis using UBA1 specific antibody
confirms efficient knockdown (KD) of UBA1 in all three
tested cell lines.

Fig. 3. UBA1 depletion sensitizes ovarian, breast, and
colorectal cancer cell lines to PARP inhibitor.
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Fig. 4. UBA1 depleted cells reduces the clonogenic potential of Olaparib treated cells in comparison to si-Control cells.
The findings are consistent in all three tested cell lines.

